Glucotrack, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Glucotrack amended multiple warrant and convertible note agreements (dated July, August, and September 2026) with unspecified holders to comply with Nasdaq listing requirements. Key changes: introduced 20% floor price on exercise/conversion prices (preventing dilution below this threshold), clarified stock split/dividend adjustment mechanics, and added make-whole cash payments (True-Up Amount) when conversion prices would fall below the floor. Specific dollar amounts, holder identities, and note principal values are redacted in this filing.
Why this rating
Nasdaq compliance amendments to existing instruments; no new capital raised, no equity dilution beyond previously issued securities, no material financial impact disclosed. Routine structural modifications.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.